Novartis CEO Warns US Biotech Investment Curbs in China Could Impede Drug Development
Trendline

Novartis CEO Warns US Biotech Investment Curbs in China Could Impede Drug Development

What's Happening? Vas Narasimhan, Chief Executive Officer of Novartis AG, has voiced concerns that proposed U.S. restrictions on biotech investments in China could impede the development of new medicines. In a Bloomberg interview, Narasimhan emphasized the critical role of technology transfer betwee
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.